- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02268435
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Phase
- La phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 19 years or older
- Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
- Disease control (response or stabilization for at least 6 months with first-line imatinib and failure of prior treatments for GIST, including at least both imatinib and sunitinib and/or regorafenib. However, patients with imatinib rechallenge will not be accrued.
- ECOG performance status of 0~2
- Resolution of all toxic effects of prior treatments to grade 0 or 1
- At least one evaluable or measurable lesion for phase I study
Adequate bone marrow, hepatic, renal, and other organ functions
- Neutrophil > 1,500/mm3
- Platelet > 75,000/mm3
- Hemoglobin > 8.0 g/dL
- Total bilirubin < 1.5 x upper limit of normal
- AST/ALT < 2.5 x ULN with no exceptions
- Creatinine < 1.5 x ULN
- Life expectancy > 12 weeks
- Women with reproductive potential must have a negative serum or urine pregnancy test; and men and women of reproductive potential must practice an effective method of avoiding pregnancy while receiving study drug.
- Washout period of previous TKIs or chemotherapy for more than 4 times the half life.
- No prior use of dovitinib or other inhibitors of FGFR except regorafenib
- Provision of a signed written informed consent
Exclusion Criteria:
- Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes.
Clinically significant cardiac disease or impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- LVEF < 45%
- Complete left bundle branch block
- Obligate use of a cardiac pacemaker
- Congenital long QT syndrome
- History or presence of ventricular tachyarrhythmia
- Presence of unstable atrial fibrillation .
- Clinically significant resting bradycardia
- Uncontrolled hypertension
- QTc > 480 msec on screening ECG
- Right bundle branch block + left anterior hemiblock
- Angina pectoris ≤ 3 months prior to starting study drug
- Acute Myocardial Infarction ≤ 3 months prior to starting study drug
- Other clinically significant heart disease
- Uncontrolled infection
- Subjects who did not tolerate previous imatinib treatment.
- Diabetes mellitus with signs of clinically significant peripheral vascular disease
- Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month 7. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands
8. Prior acute or chronic pancreatitis of any etiology 9. Malabsorption syndrome or uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2 10. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study 11. Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug 12. Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior baseline 13. Major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy 14. Known diagnosis of HIV infection 15. History of another primary malignancy that is currently clinically significant or currently requires active intervention 16. Patients with brain metastases as assessed by radiologic imaging due to symptoms clinically suspected of brain metastases 17. Alcohol or substance abuse disorder
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Dovitinib plus Imatinib
Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
|
Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Maximal tolerated dose and recommended dose
Délai: 3 years
|
Initially three patients will be treated at each dose level.
If one out of three patients experiences a DLT, three additional patients will be entered at that dose level.
Dose escalation will be continued until DLTs are experienced in two or more out of six patients (more than 33% of patient cohort), which will be defined as the MTD.If more than 33% of patients experience a DLT in a dose level, one doe level below will be the RD
|
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Disease control rate
Délai: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Overall response rate
Délai: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Number of Participants with Adverse Events as a Measure of Safety
Délai: 3 years
|
Safety by NCI CTCAE version 4.0
|
3 years
|
Progression-free survival
Délai: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Overall survival (OS)
Délai: 3 years
|
OS assessment dates will be the time point when 6 months have passed after the enrollment of the last patient
|
3 years
|
optionally, correlation of efficacy with potential biomarkers
Délai: 3 years
|
mutational analysis of KIT exons 9, 11, 13, and 17, and PDGFRα exons 12, 14, and 18 with direct sequencing using DNA extracted from archival tissues and/or newly obtained tissues at baseline, and with BEAMing assay using ctDNA extracted from plasma at baseline and every time when follow-up CT scans are conducted; optionally circulating growth factors including but not limited to VEGF, bFGF, IL-8, PLGF, FGFR2, and FGF23, and soluble receptors including but not limited to sVEGFR1 and 2 with plasma collected at baseline and on Cycle 1 Week 4 Day 5
|
3 years
|
next generation sequencing will be performed in newly obtained tissues at baseline to find out new genetic changes after failure of previous standard TKIs
Délai: 3 years
|
3 years
|
|
Optionally, activation of FGFR signaling will be analyzed using the reverse phase protein microarray and/or immunohistochemistry including but not limited to pFRS2 and pFGFR in archival tissues and/or newly obtained tissues at baseline
Délai: 3 years
|
3 years
|
|
Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters
Délai: 3 years
|
PK samples will be taken at 0 hour (pre-dose) and at 1, 2, 3, 4, 6, and 8 hours (post-dose) after administration of dovitinib and imatinib on Cycle 1 Week 1 Day 1, Cycle 1 Week 1 Day 5, and Cycle 1 Week 4 Day 5
|
3 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Yoon-Koo Kang, PhD, Asan Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Tumeurs, tissus conjonctifs et mous
- Tumeurs par type histologique
- Tumeurs
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies gastro-intestinales
- Tumeurs, tissu conjonctif
- Tumeurs stromales gastro-intestinales
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de protéine kinase
- Mésylate d'imatinib
Autres numéros d'identification d'étude
- AMC1401
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeurs stromales gastro-intestinales
-
NRG OncologyNational Cancer Institute (NCI); Canadian Cancer Trials GroupSuspenduSarcome stromal de l'endomètre de stade I du corps utérin AJCC v8 | Sarcome stromal de l'endomètre de stade II du corps utérin AJCC v8 | Sarcome stromal de l'endomètre de stade III du corps utérin AJCC v8États-Unis
-
Lei LiRecrutementRécurrence | Résultats de survie | Thérapie adjuvante | Hormonothérapie | Sarcome stromal endométrial de bas grade de l'utérus (diagnostic) | Chirurgie préservant la fertilité | Résultats de fertilitéChine
-
Centre Leon BerardRecrutement
-
Assaf-Harofeh Medical CenterInconnueSarcome des tissus mous | Ostéosarcome | Chondrosarcome | Sarcome osseux | Tumeur desmoplasique à petites cellules rondes | Sarcome stromal gastro-intestinal | Tumeur d'Ewing métastatique | Tumeur d'Ewing récurrente
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbComplétéCarcinosarcome | Léiomyosarcome | Carcinome de l'endomètre | Cancer de l'utérus | Carcinome à cellules claires | Sarcome indifférencié | Sarcome stromal endométrial de haut gradeÉtats-Unis
-
Tianjin Eye HospitalRecrutementUne nouvelle technique sandwich de kératoplastie mini-invasive pour la perforation cornéenne (STMIK)Perforation cornéenne, lenticule stromal cornéen, technique sandwichChine
-
National Cancer Institute (NCI)RecrutementCancer de l'estomac | Tumeur gastrique | Tumeur stromale gastro-intestinale (GIST) | Sarcome stromal gastro-intestinal | Tumeur stromale gastro-intestinaleÉtats-Unis
-
Frederic AmantKom Op Tegen Kanker; FWO Research Fund FlandersRecrutementCancer de l'endomètre | Sarcome stromal de l'endomètre | Tumeur stromale des cordons sexuels | Adénosarcome de l'utérus | Léiomyosarcome Utérus | Tumeur ovarienne séreuseBelgique
-
M.D. Anderson Cancer CenterComplétéCancer de l'endomètreÉtats-Unis
-
Novartis PharmaceuticalsComplétéAdénome corticosurrénalien | Sarcomes stromaux de l'endomètreAllemagne, États-Unis, Corée, République de, Hongrie, Italie, Slovaquie
Essais cliniques sur dovitinib plus imatinib
-
Novartis PharmaceuticalsComplété
-
Yonsei UniversityComplétéUne étude ouverte, multicentrique, de phase II sur le dovitinib dans le cancer avancé de la thyroïdeCancer de la thyroïdeCorée, République de
-
Abramson Cancer Center of the University of PennsylvaniaComplétéParagangliome non résécable | Phéochromocytome récurrent | Paragangliome métastatique avancé | Phéochromocytome métastatique avancé | Paragangliome récurrent | Phéochromocytome non résécableÉtats-Unis
-
Samsung Medical CenterInconnueCPNPC squameuxCorée, République de
-
Novartis PharmaceuticalsComplétéCancer du sein métastatiqueÉtats-Unis, Canada, Finlande, France, Italie, Espagne, Taïwan, Royaume-Uni
-
M.D. Anderson Cancer CenterNovartisRésilié
-
Korean Cancer Study GroupComplétéCancer de la prostate réfractaire aux hormonesCorée, République de
-
Novartis PharmaceuticalsComplétéActivations des voies tumorales inhibées par le DovitinibÉtats-Unis
-
Novartis PharmaceuticalsComplétéCancer de l'endomètre | VEGF | Tumeurs solides et cancer avancé de l'endomètre | Traitement de deuxième ligneItalie, Royaume-Uni, Espagne, Brésil, États-Unis, Corée, République de, Nouvelle-Zélande
-
Auckland District Health BoardNovartis; University of Auckland, New Zealand; IGENZ, Ltd., AucklandInconnueCarcinome rénal à cellules clairesNouvelle-Zélande